ICER evaluates drug price increases in California

20 October 2022 - Unsupported Price Increase” final report based on drugs identified through SB-17, the California drug price transparency law. ...

Read more →

ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage

7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...

Read more →

ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence

19 June 2020 - Public input on drugs of concern will be accepted through 17 July 2020. ...

Read more →

VA and ICER at three years: critics' concerns answered

15 June 2020 - As part of its national formulary management process, the Department of Veterans Affairs (VA) Pharmacy Benefits ...

Read more →

ICER identifies costliest US drug-price hikes that are not supported by new clinical evidence

8 October 2019 - In 2017 and 2018, out of nine identified drugs that had substantial price increases on top of ...

Read more →

ICER Proposes Updates to 2020 Value Assessment Framework Methods and Procedures

21 August 2019 - Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis ...

Read more →

ICER opens national call for proposed improvements to its value assessment framework

14 July 2016 - ICER solicits input on value assessment framework; will give webinar on current version July 29th. ...

Read more →